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The major findings in the comparison of the registry's U.S. patients versus ROW patients were that U.S.
patients were older and more likely to be male, of clinicians may need to act similarly to those in the ROW, where more than one-quarter of the patients followed up by the clinicians were asymptomatic mutation carriers, identified solely by genotyping.
The THAOS registry identified the duration between onset of symptoms and registration to be >4 years (10), meaning diagnosis of amyloidosis remains woefully delayed. Our knowledge of the 
